Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:

NCT ID: NCT06420700 Recruiting - Obesity Clinical Trials

Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)

Start date: January 31, 2024
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone combined gastric mucosal ablation with endoscopic sleeve gastroplasty at True You Weight Loss.

NCT ID: NCT06420622 Recruiting - Child Obesity Clinical Trials

INDIcators for Clarifying the bAckground of exTreme Obesity in childRen

INDICATOR
Start date: April 15, 2024
Phase:
Study type: Observational

The study investigates the genetic backgrounds of extreme childhood obesity (using saliva sample) and contains short online questionnaires on family history, phenotypical characteristics and hunger behavior. It is an observational study in a predefined cohort (subjects with data in CrescNet aged 0-18 with BMI measurement(s) above the 99.5th percentile). Recruitment will initially be from CrescNet data through the cooperating pediatric and adolescent medical institutions associated with these initiative of data collection in Germany.

NCT ID: NCT06416215 Recruiting - Obesity Clinical Trials

Promoting Positive Mental Health for Sustainable Eating Behaviors

PROMISE
Start date: January 30, 2024
Phase: N/A
Study type: Interventional

The main aim of the present study is to assess the effects and the effectiveness of a psychological intervention based on the principles of well-being therapy (WBT) in promoting weight-loss, sustainable and healthy eating behaviors and an optimal psychological functioning in patients with obesity.

NCT ID: NCT06412536 Recruiting - Obesity Clinical Trials

Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility

SWIFT-CORE-101
Start date: May 30, 2024
Phase:
Study type: Observational [Patient Registry]

SWIFT-CORE-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, comorbidities, and current symptoms. Site staff may collect vital signs, urine drug screens, blood draws, and urine pregnancy tests. A doctor will review medical history with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians and pharmacies to determine eligibility for clinical trials.

NCT ID: NCT06410820 Recruiting - Obesity, Morbid Clinical Trials

Ultrasound Guided Versus Land-mark Method for Spinal Anesthesia in Super Obesity Parturients

Start date: May 16, 2024
Phase: N/A
Study type: Interventional

This study will investigate whether an ultrasound-assisted technique is better than a classical land-mark technique to facilitate spinal anesthesia in the sitting position in super obese pregnant women with BMI ≥ 50 who will undergo elective cesarean section. The primary objective of this study is the rate of successful dural puncture at the first attempt. It was assumed that ultrasound could facilitate neuraxial blockade in super obese (BMI ≥ 50 kg/m2), pregnant women, according to the Who classification, whose topographic anatomy is difficult.

NCT ID: NCT06396871 Recruiting - Obesity Clinical Trials

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

PERIMED
Start date: October 16, 2023
Phase:
Study type: Observational

The goal of this cross-sectional observational study is to to perform a thorough characterization of the quantitative and qualitative differences in peripheral blood cells, and circulating factors (proteins, metabolites, lipids, extracellular vesicles) in different stages of several metabolic diseases (diabetes, obesity, non-alcoholic fatty liver disease) that share common pathophysiological mechanisms and in comparison with adult healthy controls. The main question[s] it aims to answer are: - Which are the quantitative (number and concentration) and qualtitative (characteristics, functional assays) differences in platelets in patients with metabolic diseases vs subjects without metabolic diseases - Which are the quantitative (number and concentration) and qualtitative (characteristics, functional assays) differences in leucocytes or circulating molecules in patients with metabolic diseases vs subjects without metabolic diseases

NCT ID: NCT06394882 Recruiting - Childhood Obesity Clinical Trials

FamCe-HLP- Family-centered Obesity Management Program in Primary Care Settings

Start date: September 18, 2023
Phase: N/A
Study type: Interventional

This clinical trial aims to compare the adiposity and weight status among mother-child dyads with overweight or obesity who receive the Fam-Ce-HLP intervention with the mother-child dyads with overweight or obesity who did not receive the intervention. The main question[s] it aims to answer are: - Is there a significant difference in the adiposity and weight status of mother-child dyads with overweight or obesity who received the Fam-Ce-HLP intervention compared with the mother-child dyads with overweight or obesity who did not receive the intervention? - Is there a significant difference in the health behaviors, obesity stage level, and ripple effect of mother-child dyads with overweight or obesity who received the Fam-Ce-HLP intervention compared with the mother-child dyads with overweight or obesity who did not receive the intervention? Participants will be asked to attend a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). Researchers will compare the intervention group with the treatment-as-usual group (control group) to see if there is a difference in adiposity, weight status, health behaviors, obesity stage level, and ripple effect.

NCT ID: NCT06391671 Recruiting - Pediatric Obesity Clinical Trials

The Stress-obesity Axis: a Metabolomics Approach Towards Personalized Nutrition in Adolescents

FAME
Start date: January 11, 2022
Phase:
Study type: Observational [Patient Registry]

The ultimate aim of this project is to establish a validated strategy that allows for personalized intervention in adolescents (11 to 17 years) whom are assigned a state of overweight or obesity. The investigators will assess the following hypotheses: - Weight condition is reflected by the fecal metabolome (WP1) - Emotional stress is implicated in weight condition (WP1) - Functionality of the gut microbiome is related to the diet-stress-obesity axis (WP2) - Dietary pattern impacts the fecal metabolome and gut microbiome (WP2) - Personalized dietary intervention outperforms generalized dietary approaches (WP3) Participants will: - Produce a saliva, stool and hair sample - Fill in questionnaires regarding mental health, medical health and demographic information - Fill in a food frequency questionnaire and a 24-hrecalls - Be measured (height, weight, fat% and waist circumference) The samples will be analyzed using a technique called metabolomics to identify biomarker candidates with diagnostic and/or prognostic potential. Additionally, microbiome analysis will be performed to map the microbiome of all groups.

NCT ID: NCT06391320 Recruiting - Obesity Clinical Trials

Obesity Queue Database

Start date: September 1, 2023
Phase:
Study type: Observational

To establish an obesity specific disease cohort database and form a special disease cohort, so as to provide guarantee for carrying out high-quality real-world clinical research and clinical research.

NCT ID: NCT06390904 Recruiting - Obesity Clinical Trials

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.